Tenaya Therapeutics (TNYA) Stock Price, News & Analysis

Company Overview

Tenaya Therapeutics is a clinical-stage biotechnology company dedicated to developing precision engineered cell therapies for cardiovascular disease. The firm’s primary focus lies in harnessing the regenerative potential of human pluripotent stem cells to create novel treatments aimed at repairing and restoring heart function in patients suffering from heart failure and other serious cardiac conditions. By leveraging insights into heart cell biology and advanced bioengineering techniques, Tenaya seeks to address the underlying causes of heart disease rather than merely managing symptoms.

At the core of Tenaya’s pipeline is TN-201, an allogeneic, pluripotent stem cell-derived cardiomyocyte therapy designed to engraft, electrically couple and functionally integrate with diseased myocardium. Preclinical studies have demonstrated the potential of these engineered heart cells to improve cardiac contractility and reduce adverse remodeling following myocardial injury. In addition to TN-201, the company is advancing complementary programs that explore genetic and tissue engineering approaches to enhance cell survival, delivery and therapeutic efficacy.

Founded in 2018 as a spin-out from Stanford University, Tenaya Therapeutics is headquartered in South San Francisco, California, and serves a global patient population through collaborative research partnerships and manufacturing alliances. The company has established strategic collaborations with academic institutions and contract development and manufacturing organizations (CDMOs) to support scalable production processes and ensure rigorous quality standards. Tenaya’s translational work aims to bridge scientific discovery with clinical application, positioning the company at the forefront of regenerative cardiology.

Tenaya’s leadership team brings together veterans from the biotechnology and pharmaceutical industries with deep expertise in stem cell science, cardiovascular medicine and cell therapy development. Guided by seasoned executives, scientific founders and a board with extensive experience in translational research, the company is committed to advancing its clinical programs through regulatory milestones and toward potential approval. As Tenaya continues to build its proprietary platform and expand its development footprint, it remains focused on delivering transformative therapies for patients facing life-threatening heart disease.

Key Stats

• Today's Range: $0.82 to $0.94
• 50-Day Range: $0.39 to $0.88
• 52-Week Range: $0.36 to $4.06
• Volume: 4.27 million shs
• Average Volume: 2.80 million shs
• Market Capitalization: $142.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.25
• Consensus Rating: Buy

Tenaya Therapeutics Stock Analysis - MarketRank™

Tenaya Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 318th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tenaya Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tenaya Therapeutics are expected to grow in the coming year, from ($1.35) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tenaya Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tenaya Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tenaya Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.97% of the float of Tenaya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenaya Therapeutics has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Tenaya Therapeutics has recently decreased by 10.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tenaya Therapeutics does not currently pay a dividend.

Dividend Growth

Tenaya Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.97% of the float of Tenaya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenaya Therapeutics has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Tenaya Therapeutics has recently decreased by 10.01%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 12 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

MarketBeat Follows

9 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,307.00 in company stock.

Percentage Held by Insiders

48.65% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TNYA Stock Analysis - Frequently Asked Questions

How have TNYA shares performed this year?

Tenaya Therapeutics' stock was trading at $1.43 at the beginning of 2025. Since then, TNYA stock has decreased by 38.7% and is now trading at $0.8771.

How were Tenaya Therapeutics' earnings last quarter?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) issued its earnings results on Wednesday, May, 7th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.06.

When did Tenaya Therapeutics IPO?

Tenaya Therapeutics (TNYA) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

How do I buy shares of Tenaya Therapeutics?

Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tenaya Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNYA
• CIK: 1858848
• Web: www.tenayatherapeutics.com
• Phone: 650-825-6990
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tenaya Therapeutics: $6.25
• High Price Target: $9.00
• Low Price Target: $5.00
• Potential Upside/Downside: +612.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$111.13 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -92.20%
• Return on Assets: -74.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.68
• Quick Ratio: 6.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.07 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 162,670,000
• Free Float: 83,530,000
• Market Cap: $142.68 million
• Optionable: Optionable
• Beta: 3.00